Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 476060Orphan Drug3 approvals19 trials

Onconic Therapeutics Inc.

Official website

KOSDAQ-listed drug developer behind Zastaprazan, Korea's 37th approved new drug, and the dual-target anticancer candidate Nesuparib.

As of 2026-10-09, Onconic Therapeutics Inc. has 2 Korean MFDS drug approvals, 8 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 2020 and listed on KOSDAQ in 2024, Onconic Therapeutics is a small-molecule drug developer focused on gastrointestinal and oncology indications. Its P-CAB mechanism GI therapy Zastaprazan, Korea's 37th approved new drug, received marketing approval for erosive esophagitis and gastric ulcer and launched in October 2024, while its dual PARP/Tankyrase inhibitor Nesuparib is in development across multiple indications including a domestic Phase 2 trial for pancreatic cancer, a Phase 2 investigator-initiated trial for endometrial cancer (in combination with Keytruda), and IND approval for a Phase 1b/2 trial in gastric cancer. Zastaprazan was out-licensed for Greater China to China's Livzon Pharmaceutical Group Inc. in March 2023, and the company expanded out-licensing to India in May 2024.

Products & technology

  • Zastaprazan (Jaqubo)P-CAB mechanism therapy for acid-related GI diseases (erosive esophagitis, gastric ulcer)
  • NesuparibDual PARP/Tankyrase-inhibiting targeted anticancer agent

Regulatory approvals

data.go.kr

1 Orphan Drug designations · 2021 / 2 Korean MFDS drug approvals · 2024–2025

  • OrphanJPI-5472021-04-27
    Orphan Drug designation · in development20210068545
  • MFDS drugJAQBO ODT. 20mg (Zastaprazan citrate)2025-10-30
    Drug · Prescription · Approval202502813
  • MFDS drugJAQBO Tab. 20mg(Zastaprazan citrate)2024-04-24
    Drug · Prescription · Approval202400960

Clinical trials

data.go.kr

19 MFDS clinical trial authorisations · 2017–2026 (Phase 1 8 · Phase 3 6 · Phase 2 2 · Phase 1/2 2 · Phase 1b 1)

  • Phase 3JP-1366 정2026-09-02

    6 trial sites

  • Phase 3JP-1366 정2026-07-01

    7 trial sites

  • Phase 1JLP-23022026-06-02

    2 trial sites

  • Phase 1JPI-5472026-03-09

    1 trial site

  • Phase 2JPI-5472026-01-20

    1 trial site

  • Phase 1/2JPI-5472025-12-16

    3 trial sites

  • Phase 1/2JPI-5472025-09-29

    8 trial sites

  • Phase 1JP-1366 정2025-09-12

    1 trial site

  • Phase 3JP-1366 정2025-07-01

    6 trial sites

  • Phase 1JLP-23022024-12-04

    2 trial sites

  • Phase 3JP-1366 정2024-04-26

    8 trial sites

  • Phase 1JP-1366 정2023-01-16
Show 7 more
  • Phase 1JP-1366 정2022-09-01
  • Phase 2JPI-5472022-06-21

    21 trial sites

  • Phase 3JP-1366 정2022-05-31

    9 trial sites

  • Phase 1bJPI-5472022-01-28

    7 trial sites

  • Phase 3JP-1366 정2021-12-14

    7 trial sites

  • Phase 1JP-1366 정2021-01-15

    1 trial site

  • Phase 1JPI-5472017-10-30

    6 trial sites

Global clinical trials

ClinicalTrials.gov · sponsor-matched
Show 8 more trials

R&D and key agreements

Source: DART corporate disclosure

Nesuparib · 췌장암 · 국내 임상2상 진행중

Nesuparib · 자궁내막암 · 연구자주도 국내 임상2상(키트루다 병용)

Nesuparib · 위암 · 국내 임상1b/2상 IND 승인

Nesuparib · 난소암 · 국내 임상2상 IND 신청

OCNR-100/101/102/200/300 · 고형암 · 후보/선도물질 도출 단계 · Early-stage discovery pipeline candidates

Key disclosures

KRX KIND via OpenDART
Show 22 more events

Publications

PubMed · affiliation-matched

Patents

KIPRIS · applicant-matched
Show 31 more patents

AI reads

MAA server logs · IP-verified
50
Times AI engines pulled Onconic Therapeutics Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

6
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

44
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

7
live 2
Last 7 days
36
live 4
Last 30 days
50
live 6
All time
  • OpenAIChatGPT-Userlive6
  • OpenAIOAI-SearchBot36
  • PerplexityPerplexityBot4
  • AnthropicClaudeBot2
  • MicrosoftBingbot1
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Onconic Therapeutics Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

JEIL PHARMACEUTICAL CO.,LTD1 shared

Spun off from Jeil Pharm Holdings in 2017, Jeil Pharmaceutical has licensed out its GERD drug Zastaprazan (Jaqubo) to multiple overseas partners.

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition